A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate

被引:29
作者
Serra-Guillen, C. [1 ]
Nagore, E. [1 ]
Hueso, L. [1 ]
Llombart, B. [1 ]
Requena, C. [1 ]
Sanmartin, O. [1 ]
Botella-Estrada, R. [1 ]
Guillen, C. [1 ]
机构
[1] Inst Valenciano Oncol, Dept Dermatol, Valencia 46009, Spain
关键词
SQUAMOUS-CELL CARCINOMA; FOLLOW-UP; CRYOTHERAPY; METAANALYSIS; MULTICENTER; PAIN; 5-FLUOROURACIL; EXTREMITIES; MANAGEMENT; EFFICACY;
D O I
10.1111/j.1365-2133.2010.10098.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
P>Background Photodynamic therapy (PDT) and imiquimod are two excellent treatments for actinic keratosis but are often not well tolerated by patients. Objectives To ascertain which treatment is better tolerated and which produces greater patient satisfaction. A secondary objective was to determine the factors related to the patient's tolerance to each treatment. Methods Patients with at least five actinic keratosis lesions on the face and scalp were selected. The patients were randomized to receive treatment with PDT with methyl aminolaevulinate or treatment with imiquimod. Tolerance, satisfaction and predisposition to repeat the treatment were evaluated. Results Most patients exhibited good or acceptable tolerance to both PDT and imiquimod treatment. There was a higher percentage of patients treated with PDT (93%) who were very satisfied compared with imiquimod (62%) (P = 0 center dot 004). Most patients treated with either one of the two options would repeat the same treatment. No significant relationship was found between age, sex, working time exposed to the sun, phototype and hair colour and the tolerance to both treatments. Conclusions Both PDT and imiquimod are treatments that are generally well tolerated. While both treatments provide a high level of satisfaction, PDT appears to be slightly superior in this regard.
引用
收藏
页码:429 / 433
页数:5
相关论文
共 23 条
[1]   The development of actinic keratosis into invasive squamous cell carcinoma: Evidence and evolving classification schemes [J].
Anwar, J ;
Wrone, DA ;
Kimyai-Asadi, A ;
Alam, M .
CLINICS IN DERMATOLOGY, 2004, 22 (03) :189-196
[2]  
Braakhuis BJM, 2003, CANCER RES, V63, P1727
[3]   The treatment of actinic keratoses [J].
Dinehart, SM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (01) :S25-S28
[4]   Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials [J].
Falagas, Matthew E. ;
Angelousi, Anna G. A. ;
Peppas, George .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 55 (03) :537-538
[5]   The risk of progression to invasive disease [J].
Glogau, RG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (01) :S23-S24
[6]   Pain caused by photodynamic therapy of skin cancer [J].
Grapengiesser, S ;
Gudmundsson, F ;
Larkö, O ;
Ericson, M ;
Rosén, A ;
Wennberg, AM .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2002, 27 (06) :493-497
[7]   Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: Critical review and meta-analysis of efficacy studies [J].
Gupta, Aditya K. ;
Davey, Valerie ;
Mcphail, Heather .
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2005, 9 (05) :209-214
[8]   Imiquimod for actinic keratosis: Systematic review and meta-analysis [J].
Hadley, Gina ;
Derry, Sheena ;
Moore, Robert A. .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2006, 126 (06) :1251-1255
[9]  
JAMES C, 2006, WHO CLASSIFICATION T, P30
[10]  
Jorizzo Joseph L, 2004, J Cutan Med Surg, V8 Suppl 3, P13, DOI 10.1007/s10227-004-0804-2